Anti-IL-6 [mAB1339 (OP-R003-1)]

Absolute Antibody

Anti-IL-6 [mAB1339 (OP-R003-1)]

9

This high affinity, fully human antagonistic monoclonal antibody mAb 1339 or OP-R003-1 was structurally derived from elsilimomab (B-E8, a murine anti-IL-6 mAb). In vitro studies demonstrated that mAb 1339 shares similar biological properties, including affinity and epitope specificity with its parent murine antibody. mAb 1339 detected human and monkey IL-6 but not murine or rat IL-6. No binding was observed with other IL-6 superfamily members. The binding affinity of this antibody to IL-6 was tested using ELISA. This fully human mAb inhibited the binding of IL-6 to its receptor as evidenced by flow cytometry using U266 cells and also inhibited IL-6 induced cell proliferation in murine B9, human TF1 or U266 cells (Vermot-Desroches et al., 2007). mAb 1339 inhibited the growth of multiple myeloma in presence of BMSC vitro, associated with inhibition of phosphorylation of STAT3, ERK1/2 and Akt and synergistically enhanced the cytotoxic activity of dexamethasone as well as bortezomib, lenalidomide, and perifosine. It also significantly enhanced growth inhibitory effects of dexamethasone in vivo in a SCID-hu mouse model of multiple myeloma (PMID: 19934301)

Flow Cytometry, ELISA, Neutralisation/Blocking

Research Use Only

Monoclonal

mAB1339 (OP-R003-1)

IL6

interleukin 6

BSF-2, BSF2, CDF, HGF, HSF, IFN-beta-2, IFNB2, IL-6, interleukin-6, B-cell differentiation factor, B-cell stimulatory factor 2, CTL differentiation factor, hybridoma growth factor, interferon beta-2, interleukin BSF-2

Human

IgG1

Interleukin-6

This chimeric human antibody was made using the variable domain sequences of the original Mouse IgG1 format, for improved compatibility with existing reagents, assays and techniques.

Human

-20°C,2°C to 8°C

12352203